Alliance for Clinical Trials in Oncology

Missed Alliance’s Best of ASH and SABCS webinar? It’s now available online. Learn from investigators about new advances impacting treatments for breast cancer, multiple myeloma and leukemia. https://lnkd.in/gGNP4pwK #ASH25 #SABCS25

New Trial Now Enrolling! We’re excited to share the launch of Alliance A232402 CD – The PAGODA Trial, focused on improving care for people with gastrointestinal cancers. This study, led by Gabriel Brooks, MD, MPH, of Dartmouth Geisel School of Medicine, aims to prevent treatment delays, which can significantly impact outcomes for patients. By addressing barriers and streamlining care, the PAGODA Trial seeks to ensure timely and effective treatment for those who need it most. To see if you or your site can participate, visit https://bit.ly/PAGODA26.

At the Alliance for Clinical Trials in Oncology, we share stories that highlight the progress and impact of cancer research. Click to see some of our recent media coverage. bit.ly/MarchMedia2026

🚨 New Findings in Prostate Cancer Symptom Management A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin significantly reduces hot flashes in men undergoing hormone therapy for prostate cancer. The results from Alliance A222001 were just published in the Journal of Clinical Oncology. Hot flashes affect up to 80% of men receiving androgen deprivation therapy, often disrupting sleep, energy levels, and quality of life. This study shows that oxybutynin—commonly used for overactive bladder—offers clinically meaningful improvements in both symptom frequency and severity. Key findings include: • Both 2.5 mg and 5 mg twice daily doses significantly outperformed placebo • Improvements were seen as early as the first week • Up to 79% of participants on the higher dose achieved at least a 50% reduction in hot flash scores • Treatment was generally well tolerated, with dry mouth as the most common side effect More at https://bit.ly/Stish-JCO

At the Society of Surgical Oncology’s annual meeting, Eric Miller, MD, PhD, of Ohio State and Sepideh Gholami, MD, of Northwell Health presented new insights from A022101 / NRG GI009 (ERAsur), a pivotal clinical trial exploring whether adding radiation therapy to chemotherapy can improve outcomes for patients with locally advanced colorectal cancer. 🔬This study represents a major collaborative effort between NRG Oncology and the Alliance for Clinical Trials in Oncology, leading cooperative cancer organizations. As we continue to push for more effective, personalized treatment strategies, trials like ERAsur are essential for shaping the future of colorectal cancer care. Learn more about the presentation and study details here: https://bit.ly/SSO-2026 #SSO2026

🌍 New publication alert! ✅ Results of Alliance A071401 published in Nature Medicine and led by Priscilla Brastianos, MD, a neuro-oncologist with the Mass General Brigham Cancer Institute and co-chair of the Alliance Neuro-Oncology Committee, show abemaciclib may slow growth of aggressive meningiomas with NF2 or CDK pathway mutations: 58% of high grade tumors didn’t progress at 6 months -- promising news for a disease with limited options. https://bit.ly/Brastianos bit.ly/A071401

🚨 Now Enrolling: A021901 / B LuRE Clinical Trial 🚨 Led by Thomas Hope, MD of UCSF and Suki Padda, MD of Fox Chase Cancer Center, this trial is evaluating a new treatment for patients with bronchial neuroendocrine tumors. 🔬 B LuRE is comparing a radioactive drug (a form of targeted radiopharmaceutical therapy) with standard chemotherapy to see which option offers better outcomes for people living with bronchial neuroendocrine tumors. 👉 Learn more at https://lnkd.in/dpdhFbXt

🚨 Now Enrolling! Phase III ShortStop HER2 Study (A012303) 🚨 Led by Adrienne Waks, MD, of the Dana Farber Cancer Institute, A012303 (ShortStop HER2), is Phase III clinical trial now enrolling. 👉 This study asks if people with early stage HER2 positive breast cancer who have no cancer left after neoadjuvant chemotherapy + HER2 targeted therapy, can safely have less treatment after surgery? 🔬 Learn more or share the trial information here: 👉 https://lnkd.in/g2_ZdeyD

🔍 New publication alert! Data from Alliance A032201 has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in Clinical and Translational Science by lead authors Michael Morris, MD, of Memorial Sloan Kettering Cancer Center and Nadine Norris, PhD, of the Mayo Clinic, this analysis of could lead to more personalized treatments for patients. 🔗 Learn more: https://lnkd.in/g3tHkYFi

Landmark Alliance ATOMIC trial establishes new standard of care for patients with dMMR #coloncancer. Learn more, visit https://bit.ly/ATOMIC2026 #ATOMIC #NCI #NCTN #CancerResearch #Alliance-A021502 #CRCsm